Skip to content

NTHI NTHI Proceeds From Sale Of Common Stock Pursuant To Equity Purchase Agreement

Proceeds From Sale Of Common Stock Pursuant To Equity Purchase Agreement at other companies

4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$1.88M
FuboTV
 logo
FuboTV FUBO
$95K
Lifevantage Corporation logo
Lifevantage CorporationLFVN
$84K-42.9%
BlackSky Technology logo
BlackSky TechnologyBKSY
$14.27M+179%
CTO Realty Growth logo
CTO Realty GrowthCTO
$14.13M+18,936%
Churchill Downs logo
Churchill DownsCHDN
$0

Other financials

Income statement

See full
Revenue$40.0K-7.0%
Operating income-$7.1M+77.9%
Net income-$8.8M+72.7%
EPS (diluted)-$0.38+78.7%

Balance sheet

See full
Cash & equivalents$138.6K-97.5%
Total debt$666.1K
Total equity-$13.2M-37.5%
Total assets$3.3M-60.6%

Cash flow

See full
Operating cash flow-$7.0M-23.7%
CapEx$125.0K
Free cash flow-$5.2M

Valuation

See full
Market cap$114.62M+51.0%
Enterprise value$115.15M+51.1%
P/S1,432.9×

Profitability

See full
Operating margin-46,870.7%
Net margin-51,613.3%
FCF margin-26,083.2%

Returns & leverage

See full
Return on equity338.1%
Debt / equity-0.1×
Current ratio0.1×-0.3×

Where this comes from

Reported directly by NTHI in its filing.

Tagged under the XBRL concept nthi:ProceedsFromSaleOfCommonStockPursuantToEquityPurchaseAgreement.

The official record: NTHI’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about NTHI's proceeds from sale of common stock pursuant to equity purchase agreement.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NTHI's proceeds from sale of common stock pursuant to equity purchase agreement?
NTHI (NTHI) reported proceeds from sale of common stock pursuant to equity purchase agreement of $666.53K in Q1 2026.
What does proceeds from sale of common stock pursuant to equity purchase agreement mean?
Represents cash inflows derived from the sale of common stock under specific equity purchase agreements, often associated with standby equity distribution agreements or similar facilities. This metric highlights the company's reliance on flexible, ongoing equity financing to support clinical development milestones.